Latest Updates in Oncology
ASCENT-03: Trodelvy Plus Pembrolizumab Demonstrates Significant PFS Benefit in First-Line Metastatic Triple-Negative Breast Cancer
ASCENT-03 trial shows Trodelvy plus pembrolizumab significantly improved PFS vs chemo plus pembrolizumab in first-line mTNBC patients.
FDA Approves First Maintenance Therapy for ES-SCLC: Lurbinectedin Plus Atezolizumab Extends Survival in IMforte Trial
FDA approves lurbinectedin plus atezolizumab for ES-SCLC maintenance, extending OS to 13.2 months vs 10.6 months with atezolizumab alone (HR...
FDA Grants Priority Review to Enhertu Plus Pertuzumab for First-Line HER2+ Metastatic Breast Cancer
FDA grants Priority Review for Enhertu plus pertuzumab in first-line HER2+ metastatic breast cancer, with decision expected April 2025.
FDA Approves Gemcitabine Intravesical System (Inlexzo) for BCG-Unresponsive Bladder Cancer
FDA approves gemcitabine intravesical system for BCG-unresponsive bladder cancer, showing 82% complete response rate in SunRISe-1 trial.
FDA Approves Modeyso as First Treatment for H3 K27M-Mutant Diffuse Midline Glioma
Modeyso, the first treatment option for this ultra-rare and aggressive brain tumor, is commercially available in the US.
Verzenio Achieves Overall Survival Milestone in Early Breast Cancer Competition”
Verzenio plus endocrine therapy offers statistically significant OS improvements over endocrine therapy alone in high-risk patients.
Latest in Practice Efficiency
Subcutaneous Immunotherapies in Solid Tumors: Are We Truly Expanding Access and Efficiency?
SC immunotherapy reduces chair time from 5-7 hours to 7 minutes but faces 45% reimbursement reduction and higher drug dose...
Latest in Rare Thyroid Malignancies
Primary Thyroid Lymphoma: Chemotherapy-First Approach Yields 35-Month Median Survival in 16-Patient Cohort
PTL is a rare extranodal malignancy accounting for
Latest in Healthcare Economics
Subcutaneous Immunotherapies in Solid Tumors: Are We Truly Expanding Access and Efficiency?
SC immunotherapy reduces chair time from 5-7 hours to 7 minutes but faces 45% reimbursement reduction and higher drug dose...
Latest in Health Insurance
Immune Checkpoint Inhibitors and Survival Disparities by Health Insurance Coverage Among Patients with Metastatic Cancer
ICIs widened survival gaps between insured/uninsured advanced cancer patients despite improving outcomes across all insurance groups.
Latest in Health Policy & Access
Immune Checkpoint Inhibitors and Survival Disparities by Health Insurance Coverage Among Patients with Metastatic Cancer
ICIs widened survival gaps between insured/uninsured advanced cancer patients despite improving outcomes across all insurance groups.
Latest in Regulatory Updates
ASCENT-03: Trodelvy Plus Pembrolizumab Demonstrates Significant PFS Benefit in First-Line Metastatic Triple-Negative Breast Cancer
ASCENT-03 trial shows Trodelvy plus pembrolizumab significantly improved PFS vs chemo plus pembrolizumab in first-line mTNBC patients.
FDA Approves First Maintenance Therapy for ES-SCLC: Lurbinectedin Plus Atezolizumab Extends Survival in IMforte Trial
FDA approves lurbinectedin plus atezolizumab for ES-SCLC maintenance, extending OS to 13.2 months vs 10.6 months with atezolizumab alone (HR...
FDA Grants Priority Review to Enhertu Plus Pertuzumab for First-Line HER2+ Metastatic Breast Cancer
FDA grants Priority Review for Enhertu plus pertuzumab in first-line HER2+ metastatic breast cancer, with decision expected April 2025.
FDA Approves Gemcitabine Intravesical System (Inlexzo) for BCG-Unresponsive Bladder Cancer
FDA approves gemcitabine intravesical system for BCG-unresponsive bladder cancer, showing 82% complete response rate in SunRISe-1 trial.
FDA Approves Modeyso as First Treatment for H3 K27M-Mutant Diffuse Midline Glioma
Modeyso, the first treatment option for this ultra-rare and aggressive brain tumor, is commercially available in the US.
Verzenio Achieves Overall Survival Milestone in Early Breast Cancer Competition”
Verzenio plus endocrine therapy offers statistically significant OS improvements over endocrine therapy alone in high-risk patients.